AWAKENNCT07819435
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Site details revised at 2 of 63 sites
- Minor Site details revised at 6 of 63 sites
- Minor Trial sites expanded: 22 → 63 locations
- Notable Recruitment opened
- Trial sites expanded: 17 → 22 locations
- Trial sites expanded: 0 → 17 locations
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 17
- Start date changed from estimate of Sep 2026 to Sep 21, 2026
- Minor Study title shortened, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from baseline in non-vellus target area hair count
Timeframe: Week 24
Secondary (3)
Change from baseline in the Participant Assessment of Scalp Coverage
≥20% increase from baseline in non-vellus target area hair count
Change from baseline in non-vellus target area hair count
Arms and interventions
PP405 0.05% Topical GelExperimental
PP405 applied to the scalp from Day 1 to Week 24; then continuing PP405 from Week 24 to Week 52.
Vehicle Topical GelPlacebo comparator
Vehicle applied to the scalp from Day 1 to Week 24; then re-randomized 1:1 to receive either PP405 or vehicle QD from Week 24 to Week 52
Drugs: PP405 0.05% Topical Gel, Vehicle Topical Gel
Sites
63 sites in 2 countries
United States 57, Canada 6